Amid Effective TNF-α Inhibitors, What Clinical Improvements Do Rheumatologists and Payers Expect from Emerging Therapies with a Different Mechanism of Action? Axial spondyloarthritis (Ax SpA) is…
How Will New Market Entrants Fare in the Rapidly Evolving Treatment Landscape? Affecting at least 170 million people worldwide, chronic hepatitis C virus (HCV) infections are a serious public…
Physician and Payer Perspectives on Prescribing and Patient Access China has long wrestled with an increasing prevalence in respiratory diseases that has accompanied its economic growth and…
What Clinical Improvements Will Differentiate Emerging Therapies in a Market with High Unmet Need and Rising Use of Microbiome-Based Treatments? Clostridium difficile infection (CDI) and…
Are new drug classes expected to address the considerable unmet need? Crohn’s disease (CD) is a chronic gastrointestinal inflammatory disorder affecting over 1 million people in the major…
How Receptive Are Physicians and Payers to Premium-Priced Emerging Therapies in This Underserved Market? Patients with advanced/metastatic colorectal cancer (mCRC) typically receive chemotherapy (…
A Survey of Oncologists and MCO Pharmacy and Medical Directors Targeted small-molecule agents have emerged as key treatment options for biomarker-defined non-small-cell lung cancer (NSCLC)…
Last Updated 22 April 2015 Gram-negative infections (GNIs) comprise a large portion of hospital-treated infections (HTIs), which represent a high-value segment of the antibacterial market given the…
Will the Emerging Immunotherapies and BRAF/MEK Inhibitor Combinations Meet Physicians’ and Payers’ Expectations? In recent years, several new, high-priced therapies have been approved for use…
In This Increasingly Crowded Setting, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers? Treatment decisions for non-small-cell lung cancer (NSCLC)…
What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Must Offer to Gain Traction in This Market? The introduction of the HER2-targeting agent trastuzumab (Roche/Genentech/…
Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs) and is characterized by irreversible loss of lung function leading to high…
A Survey of Noninterventional Cardiologists, Endocrinologists, and Managed Care Organization Pharmacy and Medical Directors The primary goal of therapy for individuals with dyslipidemia is to…
How Can Emerging Augmentation Strategies Be Differentiated to Maximize Uptake in a Mature and Genericized Market? Unipolar depression, which includes major depressive disorder (MDD), minor…
TreatmentTrends: Diabetic Retinopathy/Diabetic Macular Edema 2015 (US) is the fourth annual syndicated report series that offers a snapshot of DR and DME market dynamics and the competitive…
